Clinical Trial Notation: Transplantlines Food and Nutrition Biobank and Cohort Study Clinicaltrials.gov NCT02811835.

Introduction {#tri13600-sec-0001}
============

Renal transplantation has been a lifesaving treatment for end‐stage renal disease for over 60 years \[[1](#tri13600-bib-0001){ref-type="ref"}\]. Improvements in prevention and treatment of short‐term complications and overall greater quality of life have made it the preferred treatment over dialysis \[[2](#tri13600-bib-0002){ref-type="ref"}\]. The long‐term survival after renal transplantation, however, has disappointingly remained almost unchanged over the years \[[3](#tri13600-bib-0003){ref-type="ref"}, [4](#tri13600-bib-0004){ref-type="ref"}\], with half of renal transplant recipients (RTR) experiencing graft failure (defined as return to dialysis or retransplantation) or death within a decade after transplantation \[[5](#tri13600-bib-0005){ref-type="ref"}\]. This late graft failure is not only a personal disaster \[[6](#tri13600-bib-0006){ref-type="ref"}\], but also a significant burden for the healthcare system, because, nowadays, return to dialysis as a consequence of a failing graft is one of the most common reasons for initiation of dialysis \[[7](#tri13600-bib-0007){ref-type="ref"}, [8](#tri13600-bib-0008){ref-type="ref"}\]. This stresses the importance of identifying potentially modifiable risk factors for premature graft failure.

Hydrogen sulfide (H~2~S), an endogenously produced gaseous compound from the conversion of the sulfuric amino acids cysteine and methionine, has been shown to have cytoprotective properties \[[9](#tri13600-bib-0009){ref-type="ref"}, [10](#tri13600-bib-0010){ref-type="ref"}\]. The cytoprotective properties of H~2~S are based on its anti‐inflammatory, antioxidant, and anti‐apoptotic effects, which may at least in part be mediated by its ability to directly scavenge reactive oxygen species (ROS) and downregulate the ROS‐producing enzymes \[[11](#tri13600-bib-0011){ref-type="ref"}\]. For instance, the H~2~S donor NaHS has been shown to suppress expression of the ROS‐generating enzyme NADPH oxidase (NOX) and its essential subunit Rac‐1. NaHS has also been shown to attenuate homocysteine‐induced oxidative stress by inhibiting ROS production and NOX‐4 protein expression \[[12](#tri13600-bib-0012){ref-type="ref"}\]. Furthermore, NaHS has been shown to have a synergistic effect on the antioxidant properties of other agents such as apocynin, superoxide dismutase, and N‐acetyl‐cysteine \[[12](#tri13600-bib-0012){ref-type="ref"}\]. In addition, H~2~S exhibits anti‐inflammatory effects. For example, treatment of murine cells exposed to pro‐inflammatory LPS with the slow‐release H~2~S donor GYY4137 resulted in a concentration‐dependent reduction of the of production of pro‐inflammatory cytokines such as TNF‐ɑ, IL‐1β, and IL‐6 \[[13](#tri13600-bib-0013){ref-type="ref"}\]. Furthermore, specific renoprotective properties of H~2~S have been shown in mice models with hyperhomocysteinemia, where H~2~S supplementation reduced both macrophage infiltration and collagen deposition in glomeruli \[[14](#tri13600-bib-0014){ref-type="ref"}\].

Urinary sulfate excretion (USE) represents flux through the H~2~S pathway, with sulfate being an end‐metabolite of H~2~S metabolism \[[15](#tri13600-bib-0015){ref-type="ref"}\]. Consistent with cytoprotective properties on renal tissue, it has been found that high USE, reflecting high flux through this pathway, has been associated with lower rates of decline of renal function and lower risk of developing renal failure in patients with type 1 and 2 diabetes mellitus \[[16](#tri13600-bib-0016){ref-type="ref"}, [17](#tri13600-bib-0017){ref-type="ref"}\]. We hypothesized that a similar protective effect might be present in RTR and set out to investigate the association of USE with graft failure in RTR. Secondary aim was to study associations of USE with change of renal function over time.

Materials and methods {#tri13600-sec-0002}
=====================

Study population {#tri13600-sec-0003}
----------------

The cohort is part of a larger prospective cohort study (the Transplantlines Food and Nutrition Biobank and Cohort Study, Clinicaltrials.gov NCT02811835) of RTR in the northern part of the Netherlands. Adult RTR aged ≥18 years with a functioning graft for at least one year after transplantation and who visited the outpatient clinic of the University Medical Center Groningen, the Netherlands, between November 2008 and March 2011 were invited (*n* = 817). Exclusion criteria were history of drug or alcohol abuse, overt congestive heart failure, an (earlier) diagnosis of malignancy other than cured skin cancer, and insufficient understanding of the Dutch language. From these, 706 RTR agreed to participate and signed written informed consent. We excluded those without data on USE, leaving 704 RTR available for this study. Baseline was defined as the first visit for laboratory and physical measurements. All RTR were in a steady state at time of these measurements and provided written informed consent. The study protocol was approved by the Institutional Ethical Review Board (METc 2008/186), and the study has been conducted in accordance with the Declaration of Helsinki and Istanbul.

Laboratory measurements {#tri13600-sec-0004}
-----------------------

We used routine laboratory methods for plasma and urinary laboratory measurements, as used in clinical practice and described as earlier \[[18](#tri13600-bib-0018){ref-type="ref"}, [19](#tri13600-bib-0019){ref-type="ref"}\]. Blood was drawn after an overnight fasting period of 8--12 h. Twenty‐four‐hour urine was collected for the urinary laboratory measurements.

We measured USE using an ion‐exchange chromatography assay with conductivity detection (Metrohm, type 861, Herisau, Switzerland) which is described previously \[[18](#tri13600-bib-0018){ref-type="ref"}, [20](#tri13600-bib-0020){ref-type="ref"}, [21](#tri13600-bib-0021){ref-type="ref"}\]. In short, urinary samples that had been stored frozen at −80 °C until assessment were defrosted, centrifuged, and diluted 50 times with ultrapure water. After homogenization, 20 μl of the diluted sample was injected using a spark Triathlon autosampler (Spark Holland, Triathlon, Emmen, the Netherlands). Sulfate was separated from other urinary components with a Metrosep A supp 10 (100/4.0) column, using a 5 mmol/l sodium hydrogen carbonate/sodium carbonate buffer at a flow of 0.85 ml/min. Sulfate was detected using conductivity detection (Metrohm, type 861). Intra‐ and inter‐assay coefficients of variation were 2.0% and 4.3%, respectively. Estimated GFR was calculated with serum creatinine and cystatin C concentrations using the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) formula \[[22](#tri13600-bib-0022){ref-type="ref"}\]. Proteinuria was defined as urinary excretion of ≥0.5 g/24 h. Protein intake at baseline was calculated using the Maroni equation and 24 h urinary urea excretion data \[[23](#tri13600-bib-0023){ref-type="ref"}, [24](#tri13600-bib-0024){ref-type="ref"}\].

Anthropomorphic and clinical measurements {#tri13600-sec-0005}
-----------------------------------------

Waist (cm) was measured between the 10th rib and the iliac crest on bare skin. Body weight was measured in kg, body height in meters without shoes. Body mass index (BMI) was calculated as weight/height^2^. Body surface area was calculated in m^2^ with the Du Bois and Du Bois formula \[[25](#tri13600-bib-0025){ref-type="ref"}\]. Blood pressure was measured in fasting state in the morning in half‐sitting position with a Dinamap^®^ 1846 monitor (Critikon, Tampa, FL, USA) and recorded as the average of the last three of 15 successive measurements (with one‐minute intervals between the measurements).

Smoking status was categorized as never, ex or current. Alcohol intake was measured by questionnaire and reported as one of three categories: 0--10 g/24 h, 10--30 g/24 h, and \>30 g/24 h. Diabetes mellitus was diagnosed according to American Diabetes Association criteria: fasting plasma glucose ≥7.0 mmol/l and/or glycated hemoglobin (HbA1c) ≥6.5%, or use of antidiabetic medication \[[26](#tri13600-bib-0026){ref-type="ref"}\].

Outcome measurements {#tri13600-sec-0006}
--------------------

The primary outcome during follow‐up was death‐censored graft failure which was defined as insufficient transplant function necessitating the return to dialysis or retransplantation. There were 124 cases (18% of study population) censored due to death prior to end of follow‐up. The outcomes were assessed at the yearly visit to the outpatient clinic of the University Medical Center Groningen, the Netherlands. Secondary outcomes were the associations of USE with change of renal function parameters during follow‐up, using 2 time points beyond baseline, with eGFR (CKD‐EPI equation) and serum creatinine data available. End‐points were recorded until September 30, 2015, after which the database was locked.

Statistical analysis {#tri13600-sec-0007}
--------------------

We used [ibm spss]{.smallcaps} statistics version 23 (2015; IBM Corp., Armonk, NY, USA), [r]{.smallcaps} statistics version 3.2.3 (2015, R Foundation for Statistical Computing, Vienna, Austria), and [graphpad prism]{.smallcaps} version 5.04 for Windows (2010; GraphPad Software, La Jolla, CA, USA). Univariable linear regression analyses were performed on the associations of USE with baseline characteristics. For the primary analyses, we used Kaplan--Meier and log‐rank tests to test the differences in outcomes between sex‐specific tertiles of USE and we used Cox proportional hazard analyses to study the associations between USE with graft failure. In order to estimate median follow‐up, we also applied reverse Kaplan--Meier analyses, according to Schemper and Smith \[[27](#tri13600-bib-0027){ref-type="ref"}\]. In these analyses, the indicators for the censor and the events of the Kaplan--Meier analyses are reversed. We used partially cumulative models to avoid a low number of events per variable \[[28](#tri13600-bib-0028){ref-type="ref"}\]: Basic confounding variables were included cumulatively up to model 1, after which all the subsequent models included potential confounding variables in addition to model 1 only. The proportionality of hazards assumption was checked using the Schoenfield residuals test and was not violated. Interactions of USE with age, sex, BMI, eGFR, alcohol intake, urinary protein excretion, and urea excretion were tested by introducing a product term of the previously mentioned variables and USE in the Cox regression model.

For secondary analyses of potential associations of USE with change of renal function, we used mixed linear model analyses with data of eGFR (CKD‐EPI) and serum creatinine over three measuring moments. The associations were additionally adjusted for potential confounders as in the primary analyses. We used an unstructured covariance structure and assigned the intercept and slope of the models as random. We calculated predictive margins of eGFR and serum creatinine over time \[[29](#tri13600-bib-0029){ref-type="ref"}\]. The predictive margins \[+95% confidence interval (CI)\] for eGFR and serum creatinine were stratified according to tertiles of USE and plotted to give a more easily interpretable presentation of the associations.

Data are presented as mean ± standard deviation (SD) for normally distributed variables, median \[interquartile range (IQR)\] for non‐normally distributed variables, and nominal data as number (percentages). For Cox proportional hazard analyses, hazard ratios (HR) and 95% CI are presented. For the linear regression associations, standardized coefficients (st. β) are presented. A *P*‐value of ≤0.05 is regarded statistically significant.

Results {#tri13600-sec-0008}
=======

General basic characteristics at baseline are presented in Table [1](#tri13600-tbl-0001){ref-type="table"} and transplant‐related basic characteristics in Table [2](#tri13600-tbl-0002){ref-type="table"}. Median USE was 17.1 \[IQR: 13.1--21.1\] mmol/24 h. Men had higher USE than women (18.9 \[14.8--22.6\] vs. 15.0 \[11.9--19.0\] mmol/24 h). Median age was 55 \[45--63\] years, and 57% of the 704 RTR were male. In univariable linear regression, USE was positively associated with the male gender, larger body dimensions, diastolic blood pressure, alcohol intake, urea excretion, and protein intake (Table [1](#tri13600-tbl-0001){ref-type="table"}). Figure [1](#tri13600-fig-0001){ref-type="fig"} shows the association of urinary sulfate excretion with protein intake. Also, it was positively associated with living kidney donation, prednisolone dosage, and eGFR (Table [2](#tri13600-tbl-0002){ref-type="table"}). USE was inversely associated with blood triglyceride, high sensitivity C‐reactive protein (hs‐CRP), leukocyte count, and N‐terminal pro‐brain natriuretic peptide levels (Table [1](#tri13600-tbl-0001){ref-type="table"}). It was also inversely associated with time between transplantation and baseline, cold ischemia time, repetitive transplantations, serum creatinine, and proteinuria (Table [1](#tri13600-tbl-0001){ref-type="table"}).

###### 

Basic characteristics.

                                                                           *n* = 704                St. β of univariable association with 24 h sulfate excretion   *P*
  ------------------------------------------------------------------------ ------------------------ -------------------------------------------------------------- -----------
  Sulfate excretion, mmol/24 h                                             17.10 \[13.05--21.12\]   n/a                                                            n/a
  Men                                                                      18.89 \[14.76--22.60\]   n/a                                                            n/a
  Women                                                                    15.03 \[11.89--19.04\]   n/a                                                            n/a
  Demographics                                                                                                                                                     
  Age of patient (years)                                                   54.6 \[44.9--62.9\]      −0.03                                                          0.46
  Male gender, *n* (%)                                                     400 (56.8%)              0.27                                                           *\<0.001*
  Body composition                                                                                                                                                 
  Weight, kg                                                               80.4 ± 16.6              0.29                                                           *\<0.001*
  BMI, kg/m^2^                                                             26.0 \[23.2--29.4\]      0.15                                                           *\<0.001*
  BSA, m^2^                                                                1.94 ± 0.22              0.34                                                           *\<0.001*
  Blood pressure                                                                                                                                                   
  Systolic pressure, mmHg                                                  136 ± 18                 −0.03                                                          0.49
  Diastolic pressure, mmHg                                                 83 ± 11                  0.09                                                           *0.02*
  Use of antihypertensives, *n* (%)                                        621 (88.2)               −0.01                                                          0.76
  Number of antihypertensive drugs, *n* (%)                                                                                                                        
  0 antihypertensive drugs                                                 82 (11.6)                Ref.                                                           Ref.
  1 antihypertensive drugs                                                 194 (27.6)               0.02                                                           0.77
  ≥2 antihypertensive drugs                                                428 (60.8)               0.02                                                           0.77
  Lipids                                                                                                                                                           
  Total cholesterol, mmol/l                                                5.13 ± 1.13              −0.04                                                          0.26
  HDL cholesterol, mmol/l                                                  1.30 \[1.10--1.60\]      −0.02                                                          0.53
  LDL cholesterol, mmol/l                                                  2.99 ± 0.93              0.004                                                          0.92
  Triglycerides, mmol/l                                                    1.68 \[1.25--2.29\]      −0.10                                                          *0.01*
  Use of statins, *n* (%)                                                  373 (53.0)               0.002                                                          0.96
  Diabetes (at baseline)                                                                                                                                           
  Diabetes, *n* (%)                                                        168 (23.9)               −0.05                                                          0.23
  Use of antidiabetic drugs, *n* (%)                                       109 (15.5)               −0.07                                                          0.06
  Glucose, mmol/l                                                          5.3 \[4.8--6.0\]         −0.02                                                          0.68
  HbA1c, %                                                                 5.8 \[5.5--6.2\]         −0.02                                                          0.70
  Inflammation                                                                                                                                                     
  Hs‐CRP, mg/l                                                             1.60 \[0.70--4.60\]      −0.08                                                          *0.04*
  Blood leukocyte, ×10^9^/l                                                8.13 ± 2.62              −0.02                                                          0.53
  Cardiovascular disease history                                                                                                                                   
  Myocardial infarction[\*](#tri13600-note-0004){ref-type="fn"}, *n* (%)   35 (5)                   −0.03                                                          0.50
  CABG and/or PCI, *n* (%)                                                 55 (7.8)                 −0.04                                                          0.35
  CVA or TIA, *n* (%)                                                      41 (5.8)                 −0.01                                                          0.79
  Heart failure                                                                                                                                                    
  NT‐proBNP, ng/l                                                          254 \[109--623\]         −0.10                                                          *0.01*
  Smoking status, *n* (%)[^†^](#tri13600-note-0005){ref-type="fn"}                                                                                                 
  Never or ex                                                              578 (82.1)               Ref.                                                           Ref.
  Current                                                                  83 (11.8)                −0.01                                                          0.85
  Alcohol intake, *n* (%)[^†^](#tri13600-note-0005){ref-type="fn"}                                                                                                 
  0--10 g/day                                                              472 (67.0)               Ref.                                                           Ref.
  10--30 g/day                                                             139 (19.7)               0.13                                                           *0.001*
  \>30 g/day                                                               30 (4.3)                 0.11                                                           *0.01*
  Urea excretion, mmol/24 h                                                388 ± 114                0.85                                                           *\<0.001*
  Total protein intake, g/kg body weight/day                               1.09 ± 0.27              0.56                                                           *\<0.001*

BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; hs‐CRP, high‐sensitivity C‐reactive protein; CVA, cardiovascular accident; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

Data are presented as mean ± standard deviation (SD) for normally distributed variables, median \[interquartile range (IQR)\] for variables with a skewed distribution, and nominal data as number (percentages).

Significant *P* values are displayed in italics.

STEMI and/or NSTEMI.

Percentages do not add up to 100% due to missing cases.
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###### 

Transplant‐related characteristics.

                                                                                                      (*n* = 704)           St. β of univariable association with 24 h sulfate excretion   *P*
  --------------------------------------------------------------------------------------------------- --------------------- -------------------------------------------------------------- -----------
  Time between transplantation and baseline, years                                                    5.3 \[1.9--12.0\]     −0.13                                                          *0.001*
  (Pre)transplant history                                                                                                                                                                  
  Pretransplant disease[\*](#tri13600-note-0008){ref-type="fn"}, *n* (%)                                                                                                                   
  Primary glomerular disease                                                                          198 (28.1)            0.02                                                           0.66
  Glomerulonephritis                                                                                  54 (7.7)              0.02                                                           0.71
  Tubular interstitial disease                                                                        84 (11.9)             −0.08                                                          0.10
  Polycystic renal disease                                                                            146 (20.7)            −0.02                                                          0.77
  Dysplasia and hypoplasia                                                                            28 (4.0)              −0.01                                                          0.88
  Renovascular disease                                                                                40 (5.7)              −0.01                                                          0.81
  Diabetes mellitus                                                                                   36 (5.1)              −0.06                                                          0.15
  Other/unknown cause                                                                                 118 (16.8)            Ref                                                             
  Dialysis time, months                                                                               41.7 ± 25.0           −0.05                                                          0.56
  Donor type, *n* (%)                                                                                                                                                                      
  Living donor                                                                                        240 (34.1)            0.09                                                           *0.02*
  Ischemia times                                                                                                                                                                           
  Cold ischemia times (h)                                                                             15.3 \[2.8--21.2\]    −0.09                                                          *0.02*
  Warm ischemia times (min)                                                                           40 \[33--50\]         0.02                                                           0.64
  Initial immunosuppression after transplantation, *n* (%)[^†^](#tri13600-note-0009){ref-type="fn"}                                                                                        
  Corticosteroids                                                                                     22 (3.1)              −0.05                                                          0.26
  Ciclosporin A                                                                                       188 (26.7)            −0.09                                                          0.15
  Tacrolimus                                                                                          3 (0.4)               \<0.001                                                        1.00
  ATG                                                                                                 60 (8.5)              −0.02                                                          0.65
  OKT3 monoclonal AB[^‡^](#tri13600-note-0010){ref-type="fn"}                                         16 (2.3)              −0.05                                                          0.22
  Anti‐IL2R monoclonal AB                                                                             348 (49.4)            0.04                                                           0.60
  Rituximab                                                                                           2 (0.3)               −0.02                                                          0.59
  Other                                                                                               27 (3.8)              Ref.                                                           Ref.
  Rejection after transplantation up to baseline, *n* (%)                                             188 (26.7)            −0.06                                                          *0.12*
  Number of transplantations, *n* (%)                                                                                                                                                      
  1                                                                                                   635 (90.2)            Ref.                                                           Ref.
  2 or more                                                                                           69 (9.8)              −0.07                                                          *0.05*
  Immunosuppressive medication                                                                                                                                                             
  Prednisolone dosage, mg/24 h                                                                        10.0 \[7.5--10.0\]    0.10                                                           *0.01*
  CNI usage[^§^](#tri13600-note-0011){ref-type="fn"}, *n* (%)                                         404 (57.4)            −0.01                                                          0.79
  Proliferation inhibitor[^¶^](#tri13600-note-0012){ref-type="fn"}, *n* (%)                           584 (83.0)            0.06                                                           0.12
  Renal allograft function                                                                                                                                                                 
  Serum urea, mmol/l                                                                                  9.6 \[7.2--13.4\]     −0.04                                                          0.34
  Serum creatinine, µmol/l                                                                            125 \[100--161\]      −0.11                                                          *0.01*
  eGFR, ml/min/1.73 m^2^                                                                              45.0 ± 18.7           0.20                                                           *\<0.001*
  Protein excretion, g/24 h                                                                           0.20 \[0.02--0.37\]   −0.09                                                          0.02
  Proteinuria (\>0.5 g per 24 h), *n* (%)                                                             158 (22.4)            −0.12                                                          *0.002*

AB, antibody; ATG, antithymocyte globulin; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; IL2r, interleukin‐2 receptor.

eGFR was calculated according to the CKD‐EPI creatinine and cystatin C formula. Data are presented as mean ± standard deviation (SD) for normally distributed variables, median \[interquartile range (IQR)\] for variables with a skewed distribution, and nominal data as number (percentages).

Significant *P* values are displayed in italics.

Percentages do not add up to 100% because of rounding.

Percentages do not add up to 100% because of missing cases.

Muromonab‐CD3.

e.g. tacrolimus.

e.g. mycophenolate mofetil.
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![Scatterplot of total protein intake, calculated with the urea nitrogen excretion‐derived Maroni formula, and urinary sulfate excretion.](TRI-33-752-g001){#tri13600-fig-0001}

USE and graft failure {#tri13600-sec-0009}
---------------------

Median follow‐up time after baseline was 5.4 (IQR: 4.9--6.1) years according to the reverse Kaplan--Meier method. Out of 704 RTR, 84 (12%) experienced graft failure during follow‐up. The most common cause of graft failure was chronic rejection (73.8%), followed by recurrence of primary renal disease (9.5%), acute rejection (3,6%), graft infection (3,6%), other infection (3,6%), non‐operable vascular problems (2.4%), and other nonspecified causes (3,6%). In Fig. [2](#tri13600-fig-0002){ref-type="fig"}, Kaplan--Meier analysis of the associations of sex‐specified tertiles of USE with graft failure is presented. Higher sex‐specific tertiles of USE is associated with less cumulative risk of graft failure (Log‐Rank: *P* \< 0.001).

![Kaplan--Meier analyses of the associations of sex‐specific tertiles of urinary sulfate excretion with graft survival censored for death.](TRI-33-752-g002){#tri13600-fig-0002}

Cox proportional hazard analyses of the association of USE with graft failure are presented in Table [3](#tri13600-tbl-0003){ref-type="table"}. USE is inversely associated with risk of graft failure \[HR (95% CI) per 10 mmol/24 h: 0.37 (0.24--0.55), *P* \< 0.001\]. This association remained independent of adjustment for potential confounders, including age and baseline eGFR, as well as alcohol intake as an extragenous source of sulfate (Models 1--4). In addition, the association of USE with graft failure was independent of 24 h urinary urea excretion \[Model 5: HR (95% CI) per 10 mmol/24 h: 0.34 (0.15--0.78), *P* = 0.01\]. No significant interaction terms were found for the selected covariates (All *P* \> 0.05).

###### 

Cox proportional hazard analyses of USE (per 10 mmol 24 h) with graft failure.

  Models    HR \[95% CI\]                                                                                                                                                     *P*
  --------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------
  Crude     0.37 \[0.24--0.55\]                                                                                                                                               \<0.001
  Model 1   0.51 \[0.31--0.82\]                                                                                                                                               0.01
  Model 2   0.53 \[0.33--0.85\]                                                                                                                                               0.01
  Model 3   0.50 \[0.31--0.82\]                                                                                                                                               0.01
  Model 4   0.57 \[0.35--0.93\]                                                                                                                                               0.03
  Model 5   0.34 \[0.15--0.78\]                                                                                                                                               0.01
  Model 1   Crude + age, sex, baseline eGFR (creatinine and cystatin C), proteinuria, time from transplantation to baseline, BMI, smoking (never/ex or current), and hs‐CRP   
  Model 2   Model 1 + donor type (living versus postmortal), CIT, number of transplantations at baseline, and prednisolone dosage                                             
  Model 3   Model 1 + diastolic blood pressure, triglycerides, and NT‐proBNP                                                                                                  
  Model 4   Model 1 + alcohol intake (0--10 g/day, 10--30 g/day, or \>30 g/day)                                                                                               
  Model 5   Model 1 + urea excretion                                                                                                                                          

BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; hs‐CRP, high sensitivity C‐reactive protein; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; USE, urinary sulfate excretion.

Data are presented as hazard ratio \[95% confidence interval\]. A table with parameters of all covariables can be found in Table [S3](#tri13600-sup-0001){ref-type="supplementary-material"}.
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USE and renal function decline {#tri13600-sec-0010}
------------------------------

Higher USE was associated with a higher predicted eGFR and lower predicted serum creatinine at baseline (Tables [S1 and S2](#tri13600-sup-0001){ref-type="supplementary-material"}). USE was also associated with less predicted increase of serum creatinine over time, but not with predicted decline of eGFR over time (Table [S2](#tri13600-sup-0001){ref-type="supplementary-material"}). Figure [3](#tri13600-fig-0003){ref-type="fig"} provides a visualization of the associations of USE with predicted eGFR and serum creatinine and their change over time, stratified over tertiles of USE: RTR in the highest tertile have significantly less predicted increase of serum creatinine compared to RTR in the lower tertiles.

![Predicted margins of renal function markers over follow‐up time for tertiles of urinary sulfate excretion. (a) Predicted margins (+95% CI) of eGFR over time for sex‐specific tertiles of urinary sulfate excretion. (b) Predicted margins (+95% CI) of serum creatinine over time for sex‐specific tertiles of urinary sulfate excretion. The slopes of the tertiles of (a) do not significantly differ from each other (*P* = 0.11), while those of (b) are significantly different (*P* \< 0.001).](TRI-33-752-g003){#tri13600-fig-0003}

Discussion {#tri13600-sec-0011}
==========

In this prospective cohort study with 704 stable RTR, we found that USE is inversely associated with graft failure. Unadjusted, there is a risk reduction of 63% for graft failure per 10 mmol/24 h increment of USE. The association of USE with graft failure remained independent of adjustment for potential confounders. To our knowledge, this is the first time that the associations of USE with graft failure have been studied in RTR. In secondary analyses, we studied the association of USE with eGFR and serum creatinine over time. There was a significant association between USE with less serum creatinine increase over follow‐up time. The positive association of USE with eGFR was only significant at baseline. These results largely corroborate the findings of van den Born *et al*. \[[17](#tri13600-bib-0017){ref-type="ref"}\] who found that USE was associated with higher eGFR and less risk of end‐stage renal disease in a large cohort of patients with type 2 diabetes. Van den Berg *et al*. \[[18](#tri13600-bib-0018){ref-type="ref"}\] have shown before in the same study cohort that higher excretion of urinary sulfur metabolites, in particular, USE, is associated with beneficial cardiovascular parameters and less all‐cause mortality.

The biological pathway through which these findings are realized may be the H~2~S pathway. Specific renoprotective benefits of H~2~S may be protection against ischemia--reperfusion damage, involving among others downregulation of coagulation and stress response genes \[[30](#tri13600-bib-0030){ref-type="ref"}, [31](#tri13600-bib-0031){ref-type="ref"}, [32](#tri13600-bib-0032){ref-type="ref"}\]. Snijder *et al*. \[[33](#tri13600-bib-0033){ref-type="ref"}\] have shown that in hypertensive rats, administration of sodium thiosulfate reduces oxidative stress along with reduction of blood pressure, a risk factor of late graft failure \[[34](#tri13600-bib-0034){ref-type="ref"}\], and cardiac fibrosis \[[33](#tri13600-bib-0033){ref-type="ref"}\]. Sen *et al*. \[[14](#tri13600-bib-0014){ref-type="ref"}\] have shown in hyperhomocysteinemic mice that supplementation of H~2~S as sodium hydrogen sulfide in drinking water attenuated the observed adverse effects of hyperhomocysteinemia (e.g., blood pressure increase), reduction of inflammatory markers, and glomerular macrophage infiltration.

Dietary sources of sulfate are sulfur‐containing amino acids via animal or plant protein or sulfate‐rich foods(‐components), such as beer and preservatives. We found that USE has a very high correlation with urinary urea excretion, which reflects total protein intake in stable RTR \[[24](#tri13600-bib-0024){ref-type="ref"}, [35](#tri13600-bib-0035){ref-type="ref"}, [36](#tri13600-bib-0036){ref-type="ref"}\]. Additionally, USE is also strongly correlated to estimated total protein intake which can be calculated with the urea nitrogen excretion‐derived Maroni formula (Fig. [1](#tri13600-fig-0001){ref-type="fig"}) \[[23](#tri13600-bib-0023){ref-type="ref"}\]. A somewhat weaker correlation has been found for the association of USE with alcohol intake. Alcoholic beverages can be a source of exogenous sulfate intake. Earlier, alcohol intake has been found to be protective for all‐cause mortality in RTR, but has no protective effect for graft failure \[[37](#tri13600-bib-0037){ref-type="ref"}\]. Over the entire cohort, USE was independently associated with lower risk of graft failure. This association was independent of adjustment for alcohol intake. We conclude that the beneficial effect of USE on reducing the risk of premature graft failure is mainly dependent upon sulfur intake through dietary protein. Our current findings corroborate an earlier study of us where we found that low protein intake, as reflected by low 24 h urinary urea excretion, is associated with increased risk for premature graft failure in RTR \[[35](#tri13600-bib-0035){ref-type="ref"}, [36](#tri13600-bib-0036){ref-type="ref"}\]. The current guideline of the "Kidney Disease: Improving Global Outcomes" workgroup does not provide specific recommendations regarding protein intake for RTR \[[38](#tri13600-bib-0038){ref-type="ref"}\], neither does the guideline of the "National Kidney Foundation Kidney Disease Outcomes Quality Initiative" (NKF KDOQI) \[[39](#tri13600-bib-0039){ref-type="ref"}, [40](#tri13600-bib-0040){ref-type="ref"}\]. Although it should be realized that the observational nature of our study does not allow for conclusions on cause--effect relationships, our findings suggest that high USE, especially from dietary protein sources high in sulfur‐containing amino acids (methionine and cysteine), could be protective against development of graft failure. Methionine and cysteine are found in higher concentrations in animal‐based protein compared to plant‐based protein \[[41](#tri13600-bib-0041){ref-type="ref"}\]. However, at this point, how much animal protein intake would be required to achieve a meaningful reduction in risk remains inconclusive. Also, potential risks of increased animal protein intake still need to be investigated first before recommending an increased animal‐based protein intake for RTR. Future intervention studies could provide more insight into whether a diet high in methionine and cysteine is truly renoprotective.

Apart from the potential role of H~2~S~,~ another interesting potential explanation of the associations revealed in the present study is that a higher sulfate excretion represents higher sulfate bioavailability for sulfate‐conjugation of endogenous and exogenous substances, thereby increasing their water solubility and facilitating renal excretion. Levy *et al.* \[[42](#tri13600-bib-0042){ref-type="ref"}\] found that 20--30% of moderate doses of acetaminophen (1--2 g) is metabolized to its sulfur‐conjugated metabolite and that the availability of sulfate was the capacity‐limiting step. Kuchel *et al*. \[[43](#tri13600-bib-0043){ref-type="ref"}\] have shown that small intravenously administered dosages of dopamine are predominantly sulfate conjugated with little to no increase in serum‐free dopamine and blood pressure. Sulfate conjugation may therefore also function as a buffering mechanism for the variation in serum catecholamine concentrations and thereby blood pressure regulation \[[43](#tri13600-bib-0043){ref-type="ref"}, [44](#tri13600-bib-0044){ref-type="ref"}\].

Strengths of this study are its prospective study design, long follow‐up, and large study population. The ability to adjust for renal function over time using linear mixed‐effects modeling of eGFR and serum creatinine adds an important dimension to the analysis of the association of USE with graft failure. A limitation of our study is that we did not include RTR that experienced graft failure in the time between transplantation and baseline measurements. We found a positive association of USE with time between transplantation and baseline measurements. To compensate for the potential effect of healthy survivorship on USE and outcomes, we adjusted the association of USE with graft failure for the individual time between transplantation and baseline. Although the results remained materially unaffected, residual confounding caused by healthy survivor bias cannot be excluded.

Another limitation of this study is that we were not able to adjust for gasotransmitters other than H~2~S. Nitric oxide metabolism, for example, may have cross talk with H~2~S metabolism, although whether this is of mainly synergistic or antagonistic nature is still under debate and dependent of organ system and tissue concentrations \[[45](#tri13600-bib-0045){ref-type="ref"}\]. Furthermore, we could not accurately investigate the association of specific type of protein intake. Animal protein sources are of higher quality and the found associations may be linked to higher intake of animal protein \[[46](#tri13600-bib-0046){ref-type="ref"}\]. A general limitation of this study and all observational studies is that the found associations do not necessarily imply causality.

Conclusions {#tri13600-sec-0012}
===========

We have found that USE is strongly associated with reduced risk of graft failure. Potential explanations are the beneficial effects of an increased H~2~S bioavailability through protein intake, or sulfate acting as a detoxifier or catecholamine buffering mechanism. These results indicate that sulfur intake may play an important role after renal transplantation and that an increase of sulfur‐containing amino acids intake may have benefits for long‐term graft survival. However, further research is warranted to determine the mechanism underlying this association and to investigate the effects of specific dietary sources of sulfate on long‐term outcome in RTR.
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**Table S1.** Linear Mixed Models for the association of urinary sulfate excretion (per 10 mmol/24 h) and eGFR (CKD‐EPI creatinine‐based formula) over follow‐up time.

**Table S2.** Linear Mixed Models for the association of urinary sulfate excretion (per 10 mmol/24 h) and serum creatinine over follow‐up time.

**Table S3.** Cox proportional hazard analyses of the association of USE with graft failure, including parameters of all covariables.
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